These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

544 related articles for article (PubMed ID: 36307751)

  • 1. A novel stemness-hypoxia-related signature for prognostic stratification and immunotherapy response in hepatocellular carcinoma.
    Zhang G; Zhang K; Zhao Y; Yang Q; Lv X
    BMC Cancer; 2022 Oct; 22(1):1103. PubMed ID: 36307751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive value of a stemness-based classifier for prognosis and immunotherapy response of hepatocellular carcinoma based on bioinformatics and machine-learning strategies.
    Chen E; Zou Z; Wang R; Liu J; Peng Z; Gan Z; Lin Z; Liu J
    Front Immunol; 2024; 15():1244392. PubMed ID: 38694506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrated Machine Learning and Bioinformatic Analyses Constructed a Novel Stemness-Related Classifier to Predict Prognosis and Immunotherapy Responses for Hepatocellular Carcinoma Patients.
    Chen D; Liu J; Zang L; Xiao T; Zhang X; Li Z; Zhu H; Gao W; Yu X
    Int J Biol Sci; 2022; 18(1):360-373. PubMed ID: 34975338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic clinical phenotypes associated with tumor stemness in the immune microenvironment of T-cell exhaustion for hepatocellular carcinoma.
    Zhang G
    Discov Oncol; 2023 Nov; 14(1):203. PubMed ID: 37957420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of chromatin organization-related gene signature for hepatocellular carcinoma prognosis and predicting immunotherapy response.
    Chen J; Chen X; Li T; Wang L; Lin G
    Int Immunopharmacol; 2022 Aug; 109():108866. PubMed ID: 35691273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integration of single-cell RNA-seq and bulk RNA-seq to construct liver hepatocellular carcinoma stem cell signatures to explore their impact on patient prognosis and treatment.
    Liu L; Zhang M; Cui N; Liu W; Di G; Wang Y; Xi X; Li H; Shen Z; Gu M; Wang Z; Jiang S; Liu B
    PLoS One; 2024; 19(4):e0298004. PubMed ID: 38635528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrated analysis revealing a novel stemness-metabolism-related gene signature for predicting prognosis and immunotherapy response in hepatocellular carcinoma.
    Wang Y; Wan X; Du S
    Front Immunol; 2023; 14():1100100. PubMed ID: 37622118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypoxic Characteristic in the Immunosuppressive Microenvironment of Hepatocellular Carcinoma.
    Mo Z; Liu D; Rong D; Zhang S
    Front Immunol; 2021; 12():611058. PubMed ID: 33679749
    [No Abstract]   [Full Text] [Related]  

  • 9. Immunological Value of Prognostic Signature Based on Cancer Stem Cell Characteristics in Hepatocellular Carcinoma.
    Xu Q; Xu H; Chen S; Huang W
    Front Cell Dev Biol; 2021; 9():710207. PubMed ID: 34409040
    [No Abstract]   [Full Text] [Related]  

  • 10. M2-like tumor-associated macrophage-related biomarkers to construct a novel prognostic signature, reveal the immune landscape, and screen drugs in hepatocellular carcinoma.
    Qu X; Zhao X; Lin K; Wang N; Li X; Li S; Zhang L; Shi Y
    Front Immunol; 2022; 13():994019. PubMed ID: 36177006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Signature construction and molecular subtype identification based on cuproptosis-related genes to predict the prognosis and immune activity of patients with hepatocellular carcinoma.
    Peng X; Zhu J; Liu S; Luo C; Wu X; Liu Z; Li Y; Yuan R
    Front Immunol; 2022; 13():990790. PubMed ID: 36248822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The identification of N6-methyladenosine-related miRNAs predictive of hepatocellular carcinoma prognosis and immunotherapy efficacy.
    Zou R; Liu Y; Qiu S; Lu Y; Chen Y; Yu H; Zhu H; Zhu W; Zhu L; Feng J; Han J
    Cancer Biomark; 2023; 38(4):551-566. PubMed ID: 38007640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cellular senescence-related classifier based on a tumorigenesis- and immune infiltration-guided strategy can predict prognosis, immunotherapy response, and candidate drugs in hepatocellular carcinoma.
    Luo Y; Liu H; Fu H; Ding GS; Teng F
    Front Immunol; 2022; 13():974377. PubMed ID: 36458010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Construction and validation of a novel signature based on epithelial-mesenchymal transition-related genes to predict prognosis and immunotherapy response in hepatocellular carcinoma by comprehensive analysis of the tumor microenvironment.
    Gao B; Wang Y; Lu S
    Funct Integr Genomics; 2022 Dec; 23(1):6. PubMed ID: 36536232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel mitochondrial unfolded protein response-related risk signature to predict prognosis, immunotherapy and sorafenib sensitivity in hepatocellular carcinoma.
    Zhang S; Guo H; Wang H; Liu X; Wang M; Liu X; Fan Y; Tan K
    Apoptosis; 2024 Jun; 29(5-6):768-784. PubMed ID: 38493408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Construction and validation of a novel lysosomal signature for hepatocellular carcinoma prognosis, diagnosis, and therapeutic decision-making.
    Chen J; Gao G; He Y; Zhang Y; Wu H; Dai P; Zheng Q; Huang H; Weng J; Zheng Y; Huang Y
    Sci Rep; 2023 Dec; 13(1):22624. PubMed ID: 38114725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Construction and validation of 3-genes hypoxia-related prognostic signature to predict the prognosis and therapeutic response of hepatocellular carcinoma patients.
    Liu Y; Shen B; Huang T; Wang J; Jiang J
    PLoS One; 2023; 18(7):e0288013. PubMed ID: 37406019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and validation of a novel immune-related prognostic model in hepatocellular carcinoma.
    Wang Z; Zhu J; Liu Y; Liu C; Wang W; Chen F; Ma L
    J Transl Med; 2020 Feb; 18(1):67. PubMed ID: 32046766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypoxia-driven lncRNA CTD-2510F5.4: a potential player in hepatocellular carcinoma's prognostic stratification, cellular behavior, tumor microenvironment, and therapeutic response.
    Abulihaiti Z; Li W; Yang L; Zhang H; Du A; Tang N; Lu Y; Zeng J
    Mol Biol Rep; 2024 Aug; 51(1):905. PubMed ID: 39133347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic signatures of sphingolipids: Understanding the immune landscape and predictive role in immunotherapy response and outcomes of hepatocellular carcinoma.
    Zhang X; Zhuge J; Liu J; Xia Z; Wang H; Gao Q; Jiang H; Qu Y; Fan L; Ma J; Tan C; Luo W; Luo Y
    Front Immunol; 2023; 14():1153423. PubMed ID: 37006285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.